BR112022009753A2 - Fármaco para prevenir turno de diálise ou morte renal - Google Patents

Fármaco para prevenir turno de diálise ou morte renal

Info

Publication number
BR112022009753A2
BR112022009753A2 BR112022009753A BR112022009753A BR112022009753A2 BR 112022009753 A2 BR112022009753 A2 BR 112022009753A2 BR 112022009753 A BR112022009753 A BR 112022009753A BR 112022009753 A BR112022009753 A BR 112022009753A BR 112022009753 A2 BR112022009753 A2 BR 112022009753A2
Authority
BR
Brazil
Prior art keywords
shift
dialysis
death
drug
general formula
Prior art date
Application number
BR112022009753A
Other languages
English (en)
Inventor
Kurumatani Hajimu
Okada Kiyonobu
Yamada Naohiro
Kiriyama Takashi
Kano Hiroyuki
Yamada Shunsuke
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of BR112022009753A2 publication Critical patent/BR112022009753A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FÁRMACO PARA PREVENIR TURNO DE DIÁLISE OU MORTE RENAL. É provido um fármaco para prevenir turno de diálise ou morte renal, que, quando administrado na forma de uma preparação de liberação contínua contendo, como um ingrediente ativo, um composto representado pela fórmula geral (I) a um grupo específico de pacientes, pode prevenir turno de diálise ou morte renal. É provido um fármaco para prevenir turno de diálise ou morte renal, o qual compreende uma preparação oral de liberação contínua contendo, como um ingrediente ativo, um composto representado pela fórmula geral (I), o fármaco sendo usado de maneira tal que o composto representado pela fórmula geral (I) seja administrado em uma dose de 220 a 260 µg por dia a um paciente com doença glomerular primária ou nefroesclerose, que tem um nível de creatinina sérica de 2,0 mg/dL ou mais, e menor que 3,0 mg/dL e/ou distúrbio nutricional. [Na fórmula, R representa um átomo de hidrogênio ou um cátion farmaceuticamente aceitável.]
BR112022009753A 2019-12-23 2020-12-23 Fármaco para prevenir turno de diálise ou morte renal BR112022009753A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019231495 2019-12-23
PCT/JP2020/048091 WO2021132302A1 (ja) 2019-12-23 2020-12-23 透析移行又は腎死の抑制のための薬剤

Publications (1)

Publication Number Publication Date
BR112022009753A2 true BR112022009753A2 (pt) 2022-08-09

Family

ID=76574144

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022009753A BR112022009753A2 (pt) 2019-12-23 2020-12-23 Fármaco para prevenir turno de diálise ou morte renal

Country Status (10)

Country Link
US (1) US20230022200A1 (pt)
EP (1) EP4082549A4 (pt)
JP (1) JP7565912B2 (pt)
KR (1) KR20220119005A (pt)
CN (1) CN115989031A (pt)
AU (1) AU2020411858A1 (pt)
BR (1) BR112022009753A2 (pt)
CA (1) CA3164676A1 (pt)
TW (1) TW202135795A (pt)
WO (1) WO2021132302A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202317089A (zh) 2021-06-16 2023-05-01 日商東麗股份有限公司 罹患慢性腎臟病的貓的治療方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656502B1 (en) 1997-03-14 2003-12-02 Toray Industries, Inc. Sustained-release prostaglandin I derivative preparation
JP3743289B2 (ja) 1999-05-10 2006-02-08 東レ株式会社 腎不全治療薬
JP2005232003A (ja) * 2001-04-04 2005-09-02 Toray Ind Inc 尿細管間質障害の治療または予防薬
US20060217421A1 (en) 2003-05-09 2006-09-28 Hajimu Kurumatani Fortifier
EP1479383B1 (en) 2003-05-20 2006-10-04 Ethypharm Oral sustained release pharmaceutical composition
JPWO2016031949A1 (ja) * 2014-08-28 2017-06-22 東レ株式会社 慢性腎不全の治療薬

Also Published As

Publication number Publication date
AU2020411858A1 (en) 2022-07-14
WO2021132302A1 (ja) 2021-07-01
TW202135795A (zh) 2021-10-01
US20230022200A1 (en) 2023-01-26
KR20220119005A (ko) 2022-08-26
CA3164676A1 (en) 2021-07-01
EP4082549A1 (en) 2022-11-02
WO2021132302A8 (ja) 2022-08-04
CN115989031A (zh) 2023-04-18
JPWO2021132302A1 (pt) 2021-07-01
EP4082549A4 (en) 2023-09-06
JP7565912B2 (ja) 2024-10-11

Similar Documents

Publication Publication Date Title
BR112015029918A2 (pt) uso de alta dose de pridopidina para tratar a doença de huntington
BR112015004244A2 (pt) composição médica oralmente administrada
BR112014016085A8 (pt) composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
JP2018513188A5 (pt)
BR112013017302A2 (pt) formulações de imunossupressor
FI4119569T3 (fi) Konjugoituja antisense-yhdisteitä käytettäviksi hoidossa
BR112018068784A2 (pt) método para o tratamento de leucemia
BR112022009753A2 (pt) Fármaco para prevenir turno de diálise ou morte renal
BR112019002513A2 (pt) uso e dosagem de agentes terapêuticos para endometriose
BRPI0411723B1 (pt) agente redutor de colesterol no soro ou agente preventivo ou terapêutico para aterosclerose, e, kit
Okada et al. Inhibition of phosphate transporters ameliorates the inflammatory and necrotic side effects of the nitrogen-containing bisphosphonate zoledronate in mice
BR0311363A (pt) Formulação farmacêutica de liberação imediata, uso da mesma, e, método para tratar um distúrbio cardiovascular em um paciente
US20080188537A1 (en) Method of treating bipolar depression with a benzamide derivative
BR112019005214A2 (pt) composição farmacêutica compreendendo antagonista do receptor de mineralocorticoide e uso da mesma
BR112019018185A2 (pt) composição para tratar uma doença de articulação humana, e, kit.
TWI341728B (en) Combinations comprising epothilones and anti-metabolites
AU2011274652A1 (en) A combination composition comprising ibuprofen and paracetamol
RU2012106827A (ru) Применение производных 5н-дибенз/в, f/азепин-5-карбоксамида для лечения фибромиалгии
US8575211B2 (en) Synergistic combination of analgesic compounds
PT1443942E (pt) Composição farmacêutica para utilização no tratamento de patologias malignas incluindo em combinação um bisfosfonato, um inibidor de cox-2 e um taxol
US20190240173A1 (en) New use of n,n-bis-2-mercaptoethyl isophthalamide
BR112022018917A2 (pt) Agente protetor da função renal
WO2016139001A1 (en) New use of acetylsalicylic acid and derivatives thereof
Mazhar Lormetazepam/paracetamol
Chantepie Amiodarone/esomeprazole/antacid interaction